Please contact our sales representative to learn more information about this reagents.
Background
Olokizumab is an immunomodulator. It binds to interleukin 6. Hence acting as an Anti-IL-6 therapeutic aimed at inflammatory disease e.g. rheumatoid arthritis (RA). It had promising results in a phase II trial against placebo or tocilizumab for patients with moderate to severe whan.